Larn Hwang - Net Worth and Insider Trading

Larn Hwang Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Larn Hwang owns 2 companies in total, including Oncotelic Therapeutics Inc (OTLC) , and Adhera Therapeutics Inc (ATRX) .

Click here to see the complete history of Larn Hwang’s form 4 insider trades.

Insider Ownership Summary of Larn Hwang

Ticker	Comapny	Transaction Date	Type of Owner
OTLC	Oncotelic Therapeutics Inc	2019-04-22	10 percent owner
ATRX	Adhera Therapeutics Inc	2017-02-10	Chief Scientific Officer

Larn Hwang Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Larn Hwang Ownership Network

Ownership Network List of Larn Hwang

No Data

Ownership Network Relation of Larn Hwang

Larn Hwang Owned Company Details

What does Oncotelic Therapeutics Inc do?

Who are the key executives at Oncotelic Therapeutics Inc?

Larn Hwang is the 10 percent owner of Oncotelic Therapeutics Inc. Other key executives at Oncotelic Therapeutics Inc include CHIEF EXECUTIVE OFFICER Vuong Trieu , CHIEF BUSINESS OFFICER Saran Saund , and CHIEF FINANCIAL OFFICER Amit B. Shah .

Oncotelic Therapeutics Inc (OTLC) Insider Trades Summary

Over the past 18 months, Larn Hwang made no insider transaction in Oncotelic Therapeutics Inc (OTLC). Other recent insider transactions involving Oncotelic Therapeutics Inc (OTLC) include a net purchase of 1,226,888 shares made by Vuong Trieu ,

In summary, during the past 3 months, insiders sold 0 shares of Oncotelic Therapeutics Inc (OTLC) in total and bought 500,000 shares, with a net purchase of 500,000 shares. During the past 18 months, 0 shares of Oncotelic Therapeutics Inc (OTLC) were sold and 1,226,888 shares were bought by its insiders, resulting in a net purchase of 1,226,888 shares.

Oncotelic Therapeutics Inc (OTLC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncotelic Therapeutics Inc Insider Transactions

No Available Data

Larn Hwang Mailing Address

Above is the net worth, insider trading, and ownership report for Larn Hwang. You might contact Larn Hwang via mailing address: C/o Marina Biotech, Inc., 17870 Castleton Street, Suite 250, City Of Industry Ca 91748.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.